{"id":791815,"date":"2024-12-03T07:15:50","date_gmt":"2024-12-03T12:15:50","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/chemomab-to-participate-in-oppenheimers-movers-in-rare-disease-summit\/"},"modified":"2024-12-03T07:15:50","modified_gmt":"2024-12-03T12:15:50","slug":"chemomab-to-participate-in-oppenheimers-movers-in-rare-disease-summit","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/chemomab-to-participate-in-oppenheimers-movers-in-rare-disease-summit\/","title":{"rendered":"Chemomab to Participate in Oppenheimer\u2019s Movers in Rare Disease Summit"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"center\">\n        <em>\u2014Movers in Rare Disease Summit Will Include Elevator Pitches from Rare Disease Companies<br \/><\/em><br \/>\n        <em>with \u201c<\/em>Key, Near-Term, Potentially Stock-Moving Catalysts\u201d\u2014<\/p>\n<p>TEL AVIV, Israel, Dec.  03, 2024  (GLOBE NEWSWIRE) &#8212; Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that it will participate in Oppenheimer&#8217;s Movers in Rare Disease Summit on Thursday, December 12, 2024, at the Westin Grand Central in New York City. The invitation-only Rare Disease Summit will feature a day of panels, presentations and 1-on-1 investor meetings with companies working in the rare disease space.<\/p>\n<p>Chemomab management will present an Elevator Pitch and will be available for one-on-one meetings with registered attendees.\u00a0<\/p>\n<p>\n        <strong>Oppenheimer Movers in Rare Disease Summit<br \/><\/strong>\n      <\/p>\n<p>\n        <strong>Date:\u00a0<\/strong>December 12, 2024<\/p>\n<p>\n        <strong>Time of Elevator Pitch:\u00a0<\/strong>2:45-3:30 pm EST<\/p>\n<p>\n        <strong>Location:\u00a0<\/strong>Westin Grand Central, New York, NY<\/p>\n<p>\n        <strong>Format:\u00a0<\/strong> Elevator Pitch &amp; 1&#215;1 Meetings<\/p>\n<p>Please contact your Oppenheimer representative to register for the Rare Disease Summit and to schedule a 1&#215;1 meeting with Chemomab management.<\/p>\n<p>\n        <strong>About Chemomab Therapeutics Ltd.<\/strong><br \/>\n        <br \/>Chemomab is a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need. Based on the unique role of the soluble protein CCL24 in promoting fibrosis and inflammation, Chemomab developed CM-101, a first-in-class dual activity monoclonal antibody that neutralizes CCL24 and has demonstrated disease-modifying potential. In clinical and preclinical studies, CM-101 has been shown to have a favorable safety profile and has been generally well-tolerated, with the potential to treat multiple severe and life-threatening fibro-inflammatory diseases. Chemomab has reported positive results from four clinical trials of CM-101 in patients. Based on recent promising data from its Phase 2 SPRING trial in the rare liver disease primary sclerosing cholangitis (PSC), the company expects two milestones in early 2025 &#8212; FDA feedback on the design of its planned CM-101 PSC registrational trial and data from the SPRING trial open label extension. CM-101 has received FDA and EMA Orphan Drug and FDA Fast Track designations for the treatment of PSC. Chemomab\u2019s CM-101 program for the treatment of systemic sclerosis is Phase 2-ready with an open U.S. IND. For more information, visit: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=iwJ2-oz8cuae2u1gPUKvQbWT5DwB73OvNLrK5lEgIepvaHbu639lr1I4y7Z5P_smCKJXD4hBDwXxmt9acaQBGQ==\" rel=\"nofollow\" target=\"_blank\">chemomab.com<\/a>.<\/p>\n<p>\n        <strong>Contacts:<\/strong>\n      <\/p>\n<p>\n        <strong>Media and Investors<\/strong>:<br \/>Barbara Lindheim<br \/>Consulting Vice President, Investor &amp; Public Relations, <br \/>Strategic Communications<br \/>Phone: +1 917-355-9234<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=1LL9YWj8goxlZzR98zyX-5NhGr9yPQiQlMDtNZQ4Rdw5DSpEKXQOrGtb1gQNFGL30e3D6a05y0NQo35Tc8W7vrJJBWyKqIRfGFEhe10P8b-tjNxJrMwGDU82acyUaLkt\" rel=\"nofollow\" target=\"_blank\">barbara.lindheim@chemomab.com<\/a><br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Em7BF610licHivqRAuKZWquUrd_3EGzVzsdi0RPa5cexvtQGE7lWZyxb_vaUcn_H4vxmQnbq3mfWtg-adWCDig==\" rel=\"nofollow\" target=\"_blank\">IR@chemomab.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMxMjc2OSM2NjE5MDc4IzIyODU4Nzg=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/YTk5OWRjZjMtMTgwZi00M2ZiLWIwOGUtMzM0ODRlNzA0NTk0LTEyOTc0Mjg=\/tiny\/Chemomab-Therapeutics.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>\u2014Movers in Rare Disease Summit Will Include Elevator Pitches from Rare Disease Companies with \u201cKey, Near-Term, Potentially Stock-Moving Catalysts\u201d\u2014 TEL AVIV, Israel, Dec. 03, 2024 (GLOBE NEWSWIRE) &#8212; Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that it will participate in Oppenheimer&#8217;s Movers in Rare Disease Summit on Thursday, December 12, 2024, at the Westin Grand Central in New York City. The invitation-only Rare Disease Summit will feature a day of panels, presentations and 1-on-1 investor meetings with companies working in the rare disease space. Chemomab management will present an Elevator Pitch and will be available for one-on-one meetings with registered attendees.\u00a0 Oppenheimer Movers in &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/chemomab-to-participate-in-oppenheimers-movers-in-rare-disease-summit\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Chemomab to Participate in Oppenheimer\u2019s Movers in Rare Disease Summit&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-791815","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Chemomab to Participate in Oppenheimer\u2019s Movers in Rare Disease Summit - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/chemomab-to-participate-in-oppenheimers-movers-in-rare-disease-summit\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Chemomab to Participate in Oppenheimer\u2019s Movers in Rare Disease Summit - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"\u2014Movers in Rare Disease Summit Will Include Elevator Pitches from Rare Disease Companies with \u201cKey, Near-Term, Potentially Stock-Moving Catalysts\u201d\u2014 TEL AVIV, Israel, Dec. 03, 2024 (GLOBE NEWSWIRE) &#8212; Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that it will participate in Oppenheimer&#8217;s Movers in Rare Disease Summit on Thursday, December 12, 2024, at the Westin Grand Central in New York City. The invitation-only Rare Disease Summit will feature a day of panels, presentations and 1-on-1 investor meetings with companies working in the rare disease space. Chemomab management will present an Elevator Pitch and will be available for one-on-one meetings with registered attendees.\u00a0 Oppenheimer Movers in &hellip; Continue reading &quot;Chemomab to Participate in Oppenheimer\u2019s Movers in Rare Disease Summit&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/chemomab-to-participate-in-oppenheimers-movers-in-rare-disease-summit\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2024-12-03T12:15:50+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMxMjc2OSM2NjE5MDc4IzIyODU4Nzg=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/chemomab-to-participate-in-oppenheimers-movers-in-rare-disease-summit\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/chemomab-to-participate-in-oppenheimers-movers-in-rare-disease-summit\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Chemomab to Participate in Oppenheimer\u2019s Movers in Rare Disease Summit\",\"datePublished\":\"2024-12-03T12:15:50+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/chemomab-to-participate-in-oppenheimers-movers-in-rare-disease-summit\\\/\"},\"wordCount\":384,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/chemomab-to-participate-in-oppenheimers-movers-in-rare-disease-summit\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMxMjc2OSM2NjE5MDc4IzIyODU4Nzg=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/chemomab-to-participate-in-oppenheimers-movers-in-rare-disease-summit\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/chemomab-to-participate-in-oppenheimers-movers-in-rare-disease-summit\\\/\",\"name\":\"Chemomab to Participate in Oppenheimer\u2019s Movers in Rare Disease Summit - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/chemomab-to-participate-in-oppenheimers-movers-in-rare-disease-summit\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/chemomab-to-participate-in-oppenheimers-movers-in-rare-disease-summit\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMxMjc2OSM2NjE5MDc4IzIyODU4Nzg=\",\"datePublished\":\"2024-12-03T12:15:50+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/chemomab-to-participate-in-oppenheimers-movers-in-rare-disease-summit\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/chemomab-to-participate-in-oppenheimers-movers-in-rare-disease-summit\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/chemomab-to-participate-in-oppenheimers-movers-in-rare-disease-summit\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMxMjc2OSM2NjE5MDc4IzIyODU4Nzg=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMxMjc2OSM2NjE5MDc4IzIyODU4Nzg=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/chemomab-to-participate-in-oppenheimers-movers-in-rare-disease-summit\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Chemomab to Participate in Oppenheimer\u2019s Movers in Rare Disease Summit\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Chemomab to Participate in Oppenheimer\u2019s Movers in Rare Disease Summit - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/chemomab-to-participate-in-oppenheimers-movers-in-rare-disease-summit\/","og_locale":"en_US","og_type":"article","og_title":"Chemomab to Participate in Oppenheimer\u2019s Movers in Rare Disease Summit - Market Newsdesk","og_description":"\u2014Movers in Rare Disease Summit Will Include Elevator Pitches from Rare Disease Companies with \u201cKey, Near-Term, Potentially Stock-Moving Catalysts\u201d\u2014 TEL AVIV, Israel, Dec. 03, 2024 (GLOBE NEWSWIRE) &#8212; Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that it will participate in Oppenheimer&#8217;s Movers in Rare Disease Summit on Thursday, December 12, 2024, at the Westin Grand Central in New York City. The invitation-only Rare Disease Summit will feature a day of panels, presentations and 1-on-1 investor meetings with companies working in the rare disease space. Chemomab management will present an Elevator Pitch and will be available for one-on-one meetings with registered attendees.\u00a0 Oppenheimer Movers in &hellip; Continue reading \"Chemomab to Participate in Oppenheimer\u2019s Movers in Rare Disease Summit\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/chemomab-to-participate-in-oppenheimers-movers-in-rare-disease-summit\/","og_site_name":"Market Newsdesk","article_published_time":"2024-12-03T12:15:50+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMxMjc2OSM2NjE5MDc4IzIyODU4Nzg=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/chemomab-to-participate-in-oppenheimers-movers-in-rare-disease-summit\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/chemomab-to-participate-in-oppenheimers-movers-in-rare-disease-summit\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Chemomab to Participate in Oppenheimer\u2019s Movers in Rare Disease Summit","datePublished":"2024-12-03T12:15:50+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/chemomab-to-participate-in-oppenheimers-movers-in-rare-disease-summit\/"},"wordCount":384,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/chemomab-to-participate-in-oppenheimers-movers-in-rare-disease-summit\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMxMjc2OSM2NjE5MDc4IzIyODU4Nzg=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/chemomab-to-participate-in-oppenheimers-movers-in-rare-disease-summit\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/chemomab-to-participate-in-oppenheimers-movers-in-rare-disease-summit\/","name":"Chemomab to Participate in Oppenheimer\u2019s Movers in Rare Disease Summit - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/chemomab-to-participate-in-oppenheimers-movers-in-rare-disease-summit\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/chemomab-to-participate-in-oppenheimers-movers-in-rare-disease-summit\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMxMjc2OSM2NjE5MDc4IzIyODU4Nzg=","datePublished":"2024-12-03T12:15:50+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/chemomab-to-participate-in-oppenheimers-movers-in-rare-disease-summit\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/chemomab-to-participate-in-oppenheimers-movers-in-rare-disease-summit\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/chemomab-to-participate-in-oppenheimers-movers-in-rare-disease-summit\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMxMjc2OSM2NjE5MDc4IzIyODU4Nzg=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMxMjc2OSM2NjE5MDc4IzIyODU4Nzg="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/chemomab-to-participate-in-oppenheimers-movers-in-rare-disease-summit\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Chemomab to Participate in Oppenheimer\u2019s Movers in Rare Disease Summit"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/791815","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=791815"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/791815\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=791815"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=791815"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=791815"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}